On Wednesday, TD Cowen adjusted its outlook on Agilon Health Inc (NYSE:AGL), reducing the price target to $6.00 from the previous $6.50, while keeping a Hold rating on the stock.
The firm noted that Agilon Health has managed to uphold its medical margin and EBITDA guidance for 2024, despite encountering some negative prior year development (PYD) related to the year 2023. This was achieved through successful negotiations for payer relief and strategic market exits.
The company reported a positive Medicare Advantage (MA) trend of 9.1% in the first quarter of 2024 but also acknowledged a recent decrease in inpatient census that could signal a potential upside. TD Cowen decided to maintain its estimates at this early stage of the year, opting to lower the target price while reiterating the Hold rating on Agilon Health's shares.
Agilon Health's negotiations have been crucial in balancing out the negative PYD impacts, which are typically adjustments for financial estimates based on the performance of previous periods. The company's ability to maintain its guidance for 2024 indicates a stable financial outlook, as it continues to navigate the healthcare market and payer dynamics.
The moderation in inpatient census mentioned by Agilon Health could indicate a shift in healthcare utilization patterns, which may influence the company's performance. Yet, TD Cowen remains cautious, choosing to keep estimates unchanged until more definitive trends can be observed.
Investors and market watchers will likely continue to monitor Agilon Health's performance closely, as the company strives to meet its financial targets amid the evolving healthcare landscape. The new price target of $6.00 reflects the firm's current assessment of the stock's value based on the available information.
InvestingPro Insights
In light of TD Cowen's recent evaluation of agilon health Inc (NYSE:AGL), it's worth considering additional insights from InvestingPro. The company has been active in managing its capital, as evidenced by aggressive share buybacks, which can be a positive signal of management's confidence in the company's future. Furthermore, agilon health's financial position is bolstered by holding more cash than debt, providing a level of financial stability that is crucial in the dynamic healthcare industry.
From a valuation standpoint, the stock is trading at a low revenue multiple, which could suggest that it is undervalued relative to its sales. This aligns with TD Cowen's adjusted stock price target, indicating that the stock may have room for growth.
Despite this, it is important to note that analysts do not expect the company to be profitable this year, and it has not been profitable over the last twelve months. The company's gross profit margins have also been weak, which is a challenge that management needs to address.
InvestingPro Data shows a striking 80.74% revenue growth in the last twelve months as of Q4 2023, which is a robust indicator of the company’s ability to expand its sales. Still, the company’s market cap stands at $2.15 billion with a negative P/E ratio of -7.46, reflecting the current lack of profitability. Moreover, the stock has experienced a significant price decline over the last year, with a 1-year price total return of -80.75%.
For investors looking for more in-depth analysis, there are additional InvestingPro Tips available for agilon health, which can be explored to better understand the company's potential and the risks it faces. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro, where you can find a total of 10 InvestingPro Tips for agilon health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.